Hebenstreit 1986.

Methods	Allocation: randomised, no further details. Blindness: double (identical film‐coated tablets). Duration: 3 months. Design: parallel. Setting: psychiatric ward, Austria. Raters: all assessments were made by the same examiner. No reference to rater blinding was reported.
Participants	Diagnosis: symptoms of TD using AIMS. N = 35. Sex: only female. Age: range 43 to 82 years. Duration TD: not reported.
Interventions	1. Celiprolol: single dose 200 mg/day. N = 17. 2. Placebo: N = 18. All patients received additional antipsychotic medication.
Outcomes	Improvement in TD symptom using SKAUB (German version of AIMS). Quality of life. Leaving the study early. Unable to use ‐ Adverse effects: diarrhoea, hypotensive circulatory dysregulation, collapsing, cold sensation in extremities, tremor, heartburn, dizziness, sleeplessness, changes in blood pressure (systolic and diastolic) and pulse (no usable data).
Notes	No information on sponsorship. Article in German.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	"randomized"; details not reported.
Allocation concealment (selection bias)	Unclear risk	Allocation concealment not reported.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double blind, identical film‐coated tablets.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No information is provided.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Exclusions are reported but no information on whether they were accounted for or discounted from the analysis.
Selective reporting (reporting bias)	High risk	Outcome data for adverse events not fully reported.
Other bias	Low risk	The study seems to be free from other sources of bias.